Comparison of the efficacy and safety of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in paediatric patients with moderate to severe exacerbation of asthma

Bîscă, N; Cernatescu, I.; Dragomir, D; Iacomi, A.; Mirceau, M.; Orascanu, D.

doi:10.1016/s0954-6111(03)90073-4

Cited by 10 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, statistically significant improvements, of similar magnitude in both groups, were noted in mean values for the following parameters: evening PEFR (+36.9% vs +36.2%); FEV 1 (+42.9% vs +40.0%); forced vital capacity (FVC; +27.8% vs +33.3%); symptom scores (morning scores were reduced from 1.8 to 0.4 in both groups); and the use of rescue medication (reduced from 0.8-0.9 to 0.2-0.3 puffs per day in both groups). Overall, approximately 90-100% of investigators and patients rated the study treatments as 'good' or 'excellent', with no significant differences between the treatments [74].…”

Section: A C C E P T E D Article In Pressmentioning

confidence: 98%

“…Randomized, double-blind studies have shown that nebulized BDP is equally as effective as BDP administered via a pMDI plus spacer in children and adults with asthma [74][75][76]. In a multicenter trial, for instance, 151 children aged 6-16 years, and with moderate-to-severe asthma exacerbations (as defined by the National Heart, Lung, and Blood Institute [NHLBI]), were randomized to receive 4 weeks' treatment with nebulized BDP 800 µg twice daily (n=75), or M A N U S C R I P T…”

Section: Nebulized Bdp Is As Effective As Bdp Via Pmdi Plus Spacermentioning

confidence: 99%

“…BDP 400 µg twice daily administered via a pMDI plus spacer (n=76) [74]. Over the course of the trial, respective increases in the primary study endpoint, morning PEFR, were +38.1% and +41.3%, with no significant difference between the two treatment regimens.…”

Section: A C C E P T E D Article In Pressmentioning

confidence: 99%

“…Regarding nebulized BDP, clinical trials reveal that this ICS formulation is generally well tolerated [68,[74][75][76][77][78][79][80]. A postal questionnaire completed by 117 patients using nebulized therapy for asthma, bronchiectasis, or chronic obstructive pulmonary disease identified that chest tightness, dry eyes, dry mouth, headache, tachycardia, and tremor were frequent adverse effects [30].…”

Section: A C C E P T E D Article In Pressmentioning

confidence: 99%

“…However, in the aforementioned trials, treatment-related adverse effects induced by nebulized BDP were generally uncommon [68,[74][75][76][77][78][79]. Most such effects were mild or moderate in severity [68,74,75,77,79], and were usually associated with the respiratory system [75,79].…”

Section: A C C E P T E D Article In Pressmentioning

confidence: 99%

See 4 more Smart Citations

Inhaled corticosteroid therapy with nebulized beclometasone dipropionate

Nicolini

Cremonesi

Melani

2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Inhaled corticosteroids (ICS) are the most effective anti-inflammatory agents for the management of chronic persistent asthma, and are therefore recommended as first-line antiasthmatic therapy in children and adults. In various settings, the administration of ICS via nebulizer rather than hand-held inhaler (HHI) may have certain advantages, as many patients with HHI fail to use these devices properly or efficiently. In particular, young children, the elderly, the acutely ill, and those with restricted dexterity may be unable to coordinate inhalation with actuation of the device or to generate sufficient inspiratory flow to operate breath-actuated devices effectively. Compliance with nebulized therapy may also be better than that with a pressurized metered-dose inhaler (pMDI) plus spacer. Systematic reviews conclude that there is no significant difference in clinical effects between nebulizers and HHI. Performance and clinical effect of nebulization are influenced by several technical aspects such as the nebulizer-drug combination, nebulizer type, output and lung deposition. Among the currently available ICS, nebulized beclometasone dipropionate (BDP) has been in clinical use for more than 35 years, and has demonstrated marked clinical efficacy and a favorable tolerability profile in children and adults with chronic persistent asthma. The clinical efficacy of nebulized beclometasone is discussed in the present review using data from 13 published studies, which included a total of 1250 patients. Three multicenter, randomized, double-blind studies showed that nebulized BDP is as effective as BDP via pMDI plus spacer in a 2:1 dose ratio. Controlled trials involving 497 adults and children demonstrated similar clinical efficacy between nebulized BDP and either nebulized fluticasone propionate or nebulized budesonide. In all these trials, treatment-related adverse effects were generally uncommon, most were mild to moderate in severity, and most were associated with the respiratory system. Metaanalyses show that BDP, like other inhaled corticosteroids, has no major influence on patient height, urinary cortisol concentration, or bone metabolism, thus suggesting the absence of growth retardation or any marked effect on adrenal function or the hypothalamic-pituitaryadrenal axis when used in the approved dose range. M A N U S C R I P T A C C E P T E D ARTICLE IN PRESSOverall, nebulized BDP appears to have a particularly important place in asthma therapy: as a general alternative to HHIs (e.g. in patients with poor HHI compliance); when patients such as children or the elderly are unable to operate HHIs because of poor hand-lung coordination, lack of cooperation, or low inspiratory flow rate; and when high dosages of ICS are required, such as in adults with severe, corticosteroid-dependent asthma.

show abstract

Section: A C C E P T E D Article In Pressmentioning

confidence: 98%

Section: Nebulized Bdp Is As Effective As Bdp Via Pmdi Plus Spacermentioning

confidence: 99%

Section: A C C E P T E D Article In Pressmentioning

confidence: 99%

Section: A C C E P T E D Article In Pressmentioning

confidence: 99%

Section: A C C E P T E D Article In Pressmentioning

confidence: 99%

See 3 more Smart Citations

Inhaled corticosteroid therapy with nebulized beclometasone dipropionate

Nicolini

Cremonesi

Melani

2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2003

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract